Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Publication date
2021-05-11
Authors
van Breeschoten, Jesper
Wouters, Michel W J M
Hilarius, Doranne L
Haanen, John B
Blank, Christian U
Aarts, Maureen J B
van den Berkmortel, Franchette W P J
de Groot, Jan-Willem B
Hospers, Geke A P
Kapiteijn, Ellen
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021
Keywords
Taverne, Oncology, Cancer Research, Published Erratum
Citation
van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, Ten Tije, B-J J, van der Veldt, A A M, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis', British Journal of Cancer, vol. 124, no. 10, 1746. https://doi.org/10.1038/s41416-021-01312-1